07:00 , Sep 28, 2015 |  BC Week In Review  |  Company News

The Gores Group, Mallinckrodt deal

Mallinckrodt will acquire Therakos Inc. from investment firm Gores for $1.3 billion in cash in a deal slated to close this quarter. Therakos markets the Cellex photopheresis system in the U.S. for palliative treatment of...
07:00 , Oct 22, 2012 |  BC Week In Review  |  Company News

J&J, The Gores Group LLC deal

Investment firm Gores will acquire Therakos Inc. (Raritan, N.J.) from the Ortho-Clinical Diagnostics Inc. subsidiary of Johnson & Johnson. Therakos markets the Therakos Cellex Photopheresis System for the palliative treatment of skin manifestations of cutaneous...
07:00 , Mar 30, 2009 |  BC Week In Review  |  Clinical News

Therakos Cellex photopheresis system regulatory update

FDA approved a PMA from Johnson & Johnson 's Therakos Inc. subsidiary for its Therakos Cellex Photopheresis System for the palliative treatment of skin manifestations of cutaneous T cell lymphoma (CTCL) that are unresponsive to...
07:00 , Jul 19, 1999 |  BC Week In Review  |  Company News

Cellex supply/service news

The U.S. Bankruptcy Court for the District of Minnesota confirmed CLXX's modified reorganization plan that will grant Biovest LLC control of the company subject to an additional $265,000 investment in CLXX and the payment of...
08:00 , Feb 16, 1999 |  BC Week In Review  |  Company News

Cellex supply/service news

The U.S. Bankruptcy Court for the District of Minnesota approved a debtor-in-possession financing agreement between CLXX and Biovest LLC under which Biovest will finance the reorganization of CLXX. Biovest advanced $685,000 to CLXX and anticipates...
08:00 , Dec 14, 1998 |  BC Week In Review  |  Company News

Cellex supply/service news

CLXX will file for bankruptcy reorganization under Chapter 11. The reorganization replaces a recapitalization plan announced last July (see BioCentury, July 6). Cellex Biosciences Inc. (CLXX), Minneapolis, Minn.   Business: Supply/Service  ...
08:00 , Mar 9, 1998 |  BC Week In Review  |  Company News

Cellex, Unisyn Technologies Inc. deal

Unisyn's board terminated the companies' merger agreement, alleging among other things that CLXX's financial performance and financial condition had declined since the agreement was signed (see BioCentury, Oct. 27, 1997). CLXX, which denied Unisyn's claims,...
08:00 , Oct 27, 1997 |  BC Week In Review  |  Company News

Cellex, Unisyn Technologies Inc. deal

CLXX and Unisyn signed a definitive merger agreement (see BioCentury, Sept. 8). CLXX will issue about 8 million new shares of common stock to Unisyn shareholders, which is equal to the total number of CLXX...
07:00 , Sep 8, 1997 |  BC Week In Review  |  Company News

Cellex, Unisyn Technologies Inc. deal

The companies announced their intention to merge in a stock transaction under which Unisyn would become a part of CLXX. The merged company will combine CLXX's fermentation systems, perfusion technologies, freeze dryers and contract production...
07:00 , Aug 11, 1997 |  BC Week In Review  |  Company News

Cellex management update

Cellex Biosciences Inc. (CLXX), Minneapolis, Minn.   Business:Supply/Service   Promoted: Bernard Horwath as president and general manager, Perfusion Technologies division; formerly VP and general manager of bioprocessing  ...